Core Viewpoint - The Medical Health Index (980016) experienced a decline of 1.04%, closing at 6286.72 points on January 20, with a total transaction volume of 27.088 billion yuan and a turnover rate of 0.91% [1] Group 1: Index Performance - On the day of reporting, 16 constituent stocks of the Medical Health Index increased, with Xinhecheng leading the gain at 3.42%, while 33 stocks declined, with Dize Pharmaceutical leading the drop at 5.1% [1] Group 2: Capital Flow - The net outflow of main funds from the Medical Health Index constituent stocks totaled 1.264 billion yuan, while retail investors saw a net inflow of 1.253 billion yuan, and speculative funds had a net inflow of 10.5153 million yuan [2] - In the past 10 days, there was an adjustment in the Medical Health Index constituent stocks, with one stock added and one stock removed [2]

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the biopharmaceutical industry, focusing on several key companies and their projected performance for 2025 and beyond. The overall sentiment reflects a robust growth trajectory within the sector. Key Companies and Their Projections 1. WuXi AppTec (药明康德) - Expected revenue for 2025 is 454.56 billion CNY, a year-on-year increase of 15.84% - Adjusted net profit is projected to be 149.57 billion CNY, up 41.33%, with total net profit reaching 191.51 billion CNY, a 102.65% increase [2] - The company has 24 GLP-1 drug candidates, with 15 in Phase II and III clinical trials, indicating strong pipeline growth [4] 2. Kanglong Chemical (康龙化成) - Anticipates revenue between 138.72 billion CNY and 142.4 billion CNY, reflecting a growth of 13%-16% - Adjusted net profit is expected to be between 17.68 billion CNY and 18.48 billion CNY, a growth of 10%-15% [2] 3. Sunway Pharma (阳光诺和) - Projected revenue between 1.192 billion CNY and 1.37 billion CNY, a growth of 10.57%-27.15% - Expected net profit between 190 million CNY and 229 million CNY, a growth of 7.69%-29.23% [2] 4. AstraZeneca (阿斯利康) - Focused on cardiovascular, ADC, next-generation IO, and cell therapy TCE areas - Key clinical data readouts expected in 2026, which may impact market dynamics [5] 5. Gilead Sciences (吉利德) - Key projects include Cloud Native Top two ADC, expected to show promising data in TNBC treatment and potential approval in the second half of the year [8] - Anticipates significant changes in the first-line triple-negative breast cancer market due to the SG molecule [8] 6. DZD Pharma (迪哲医药) - DZD6,008 shows significant efficacy in non-small cell lung cancer (NSCLC) with an ORR of 60% and PFS exceeding 10 months [3][16] Clinical Trials and Data Readouts - Multiple companies, including Gilead, AstraZeneca, and others, are set to release important clinical trial data in 2026, which could reshape competitive dynamics in the NSCLC market [16] - AstraZeneca's ADC project 18.2 is expected to have significant clinical data readouts in 2026, with a focus on large-scale Phase III trials [7] Strategic Collaborations and Market Expansion - WuXi Biologics (药明生物) has signed a strategic cooperation memorandum with Qatar Free Zone Authority to expand into the Middle East market [4] - The conference highlighted the increasing participation of Chinese companies in the global pharmaceutical market, particularly in the dual-antibody and ADC sectors [22] Emerging Trends and Innovations - The industry is witnessing a shift towards L2.0 and ADC combinations, which are expected to become the next wave of drug development [17][18] - The importance of speed and mechanism synergy in new drug development was emphasized, indicating that early-stage projects have a higher success rate [18] Conclusion - The biopharmaceutical industry is poised for significant growth, with several companies reporting strong projections and innovative clinical developments. The upcoming clinical data releases in 2026 are anticipated to have a substantial impact on market dynamics and competitive positioning within the sector.

2022 年限制性股票激励计划首次授予的第一类激励激励对象第三个归 属期第一次归属以及首次授予的第二类激励激励对象第二个归属期部 分归属、预留授予的激励对象第一个归属期部分归属结果 暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688192 证券简称：迪哲医药 公告编号：2026-003 迪哲（江苏）医药股份有限公司 本次股票上市流通日期为2026 年 1 月 19 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，迪哲（江苏）医药股份有限公司（以下简称"公司"）于 近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》， 公司完成了 2022 年限制性股票激励计划（以下简称"限制性股票激励计划"）首次 授予的第一类激励对象第三个归属期第一次归属以及首次授予的第二类激励对象 第二个归属期部分归属、预留授予的激励对象第一个归属期部分归属的股份登记 工作，现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 重要内容 ...

Core Viewpoint - The company, DiZhe Pharmaceutical, aims to innovate and transform the Chinese pharmaceutical industry by developing original drugs that benefit global patients, with a projected revenue increase and reduced losses in the coming years [2][5]. Financial Performance - For the fiscal year 2025, DiZhe Pharmaceutical expects to achieve approximately 800 million yuan in revenue, representing a year-on-year increase of about 122.28% [5]. - The company anticipates a net loss of around 770 million yuan for 2025, which is a reduction of approximately 8.98% compared to the previous year [5]. - In 2024, the company reported a revenue of 360 million yuan, marking a significant year-on-year growth of 294.24% [4]. Research and Development - Over the past eight years, DiZhe Pharmaceutical has invested over 4.7 billion yuan in research and development, with a cumulative R&D expense rate of approximately 291% relative to its revenue of 1.37 billion yuan [8]. - The R&D expenses for 2025 are projected to be around 860 million yuan, an increase of 18.84% from the previous year [8]. Product Development and Market Strategy - DiZhe Pharmaceutical has received approval for two products, Shuwotai (舒沃替尼片) and Gaoruizhe (高瑞哲胶囊), which will be included in the national medical insurance drug list, enhancing patient accessibility and market share [5][9]. - The company is focusing on global strategic expansion and plans to issue overseas listed foreign shares on the Hong Kong Stock Exchange to enhance its international brand image and competitiveness [11]. Financial Health - The company's asset-liability ratio reached 98.70% at one point, indicating a precarious financial position, but improved to 49.39% and 51.15% by the second and third quarters of 2025, respectively [10][11].

中国经济网北京1月13日讯 迪哲医药(688192.SH)昨晚披露2025年年度业绩预亏公告。经财务部门初 步测算，预计2025年度实现营业收入80,000万元左右，比上年同期增加44,010万元左右，同比增加 122.28%左右；预计2025年度归属于母公司所有者的净亏损77,000万元左右，比上年同期减少亏损7,596 万元左右，同比亏损减少8.98%左右；预计2025年度归属于母公司所有者的扣除非经常性损益后的净亏 损85,000万元左右，比上年同期减少亏损4,889万元左右，同比亏损减少5.44%左右。 迪哲医药2次募资合计募集资金38.99亿元。 2019年至2024年，公司营业收入分别为4,101.75万元、2,776.08万元、1,028.54万元、0元、9,128.86 万元和3.60亿元，归属于上市公司股东的净利润分别为-4.46亿元、-5.87亿元、-6.70亿元、-7.36亿 元、-11.08亿元和-8.46亿元，归属于上市公司股东的扣除非经常性损益的净利润分别为-4.49亿元、-3.93 亿元、-6.82亿元、-7.85亿元、-11.61亿元和-8.99亿元，经营活动产生的现金流量净额 ...

截至2026年1月12日收盘，迪哲医药(688192)报收于66.94元，上涨0.22%，换手率0.76%，成交量3.45万 手，成交额2.31亿元。 公司公告汇总 迪哲医药：2025年年度业绩预亏公告 迪哲医药预计2025年度实现营业收入80,000万元左右，同比增长122.28%；研发费用为86,000万元左 右，同比增长18.84%；归属于母公司所有者的净亏损77,000万元左右，同比减少亏损8.98%。亏损主要 因持续高研发投入所致。公司两款产品舒沃哲和高瑞哲纳入国家医保目录，海外市场亦有突破，舒沃哲 获FDA批准并被列入NCCN指南。在研产品多项临床进展公布，并获FDA快速通道认定。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 当日关注点 交易信息汇总资金流向 1月12日主力资金净流入457.75万元，占总成交额1.98%；游资资金净流入706.25万元，占总成交额 3.05%；散户资金净流出1163.99万元，占总成交额5.03%。 业绩披露要点业绩预告 迪哲医药发布业绩预告，预计2025年全年营业收入8亿元。迪哲医 ...

Group 1: WuXi AppTec - WuXi AppTec expects a revenue of approximately RMB 45.456 billion for 2025, representing a year-on-year growth of about 15.84%, with a 21.40% increase in revenue from continuing operations [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1] Group 2: Shanghai Port Group - Shanghai Port Group reported a total revenue of RMB 39.44 billion for 2025, which is a year-on-year increase of 3.5% [2][3] - The net profit attributable to shareholders decreased by 10.4% to RMB 13.4 billion [2][3] - The net profit attributable to shareholders, excluding non-recurring gains and losses, fell by 8.1% to RMB 12.2 billion [2][3] Group 3: Zangge Mining - Zangge Mining forecasts a net profit attributable to shareholders between RMB 3.7 billion and RMB 3.95 billion for 2025, indicating a growth of 43.41% to 53.10% year-on-year [4] - The net profit, excluding non-recurring gains and losses, is expected to be between RMB 3.87 billion and RMB 4.12 billion, reflecting a growth of 51.95% to 61.76% [4] Group 4: Sanan Optoelectronics - Sanan Optoelectronics anticipates a net loss attributable to shareholders between RMB -200 million and RMB -400 million for 2025, compared to a profit of RMB 253 million in the previous year [5] - The net profit, excluding non-recurring gains and losses, is expected to be between RMB -750 million and RMB -850 million [5] Group 5: JA Solar Technology - JA Solar Technology projects a net loss attributable to shareholders between RMB -4.5 billion and RMB -4.8 billion for 2025 [12] - The company maintains a leading position in battery module shipments, but faces significant pressure on sales prices and profitability due to industry competition and supply-demand imbalances [12] Group 6: Rongbai Technology - Rongbai Technology expects a net loss attributable to the parent company between RMB -150 million and RMB -190 million for 2025 [18] - The company anticipates a turnaround in the fourth quarter with a projected net profit of approximately RMB 30 million [18] Group 7: Sanxiang New Materials - Sanxiang New Materials forecasts a net profit attributable to shareholders between RMB 100 million and RMB 130 million for 2025, representing a year-on-year growth of 31.99% to 71.58% [21] - The company is focusing on expanding its zirconium product chain and optimizing its customer structure to enhance profitability [21]

北京商报讯（记者 王寅浩 宋雨盈）1月12日，迪哲医药发布2025年度业绩预亏公告，公司2025年度预计 实现营业收入约8亿元，同比增加约122.28%。归属于母公司所有者的净亏损约7.7亿元，同比亏损减少 约8.98%。归属于母公司所有者的扣除非经常性损益后的净亏损约8.5亿元，同比亏损减少约5.44%。 ...

迪哲医药(688192.SH)发布公告，公司预计2025年度归属于母公司所有者的净亏损7.7亿元左右，比上年 同期减少亏损7,596万元左右，同比亏损减少8.98%左右。 ...

智通财经APP讯，迪哲医药(688192.SH)发布公告，公司预计2025年度归属于母公司所有者的净亏损7.7 亿元左右，比上年同期减少亏损7,596万元左右，同比亏损减少8.98%左右。 ...